1-2 of 2
potentially inappropriate medication list
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

Lucia Mazzacurati, Robert J. Collins, Garima Pandey, Que T. Lambert-Showers, Narmin E. Amin, Ling Zhang, Matthew C. Stubbs, Pearlie K. Epling-Burnette, Holly K. Koblish, Gary W. Reuther
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3503–3514.
https://doi.org/10.1182/bloodadvances.2019000260
Published: 2019
Includes: Supplemental data
Journal Articles

Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting

Ralf Buettner, Corey Morales, Enrico Caserta, Estelle Troadec, Emine G. Gunes, Domenico Viola, Jihane Khalife, Hongzhi Li, Jonathan J. Keats, Austin Christofferson, Xiwei Wu, Timothy W. Synold, Joycelynne Palmer, James F. Sanchez, Alexander Pozhitkov, Nagarajan Vaidehi, Guido Marcucci, Amrita Krishnan, Michael A. Rosenzweig, Flavia Pichiorri, Steven T. Rosen
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1027–1032.
https://doi.org/10.1182/bloodadvances.2018027227
Published: 2019
Includes: Supplemental data